Population PK Modeling and Exposure-Response Analyses of Sorafenib in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer (Rai-Rdtc) in the Phase III DECISION Trial.

Lars Bastholt,Marcia S. Brose,Barbara Jarzab,Martin Schlumberger,Salvatore Siena,Christelle De La Fouchardiere,Ralf Paschke,Hari Anant Deshpande,Yuankai Shi,Rossella Elisei,Ming Gao,Lin Li,Klaas Prins,Helen Walker,David Y. Mitchell,John T. Lettieri,Istvan Molnar,Christian Kappeler,Carol Elaine Pena
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.6061
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:6061^ Background: The recently reported phase III DECISION trial in patients with RAI-rDTC demonstrated a significant improvement in progression free survival (PFS) associated with sorafenib treatment. The purpose of this exploratory analysis was to evaluate sorafenib pharmacokinetics (PK) in RAI-rDTC and to examine the relationship between exposure and both PFS and adverse events (AEs). Methods: In DECISION, patients with locally advanced/metastatic RAI-rDTC who progressed in the prior 14 months were randomized to sorafenib 400 mg bid po or placebo. Plasma was collected on Cycle 2 Day 1 (steady state) and sorafenib concentrations measured using LC-MS/MS. Sorafenib AUC(0-12),ss were estimated using a population PK model developed from 10 sorafenib phase I-III trials, including DECISION. Results: Plasma samples from 156 patients randomized to sorafenib were valid for the analysis. Sorafenib mean AUC(0-12),ss (95.7 mg*h/L) was 103% higher in DTC compared to RCC and HCC, although the ranges of AUCs were overlapping. No specific mechanism for the elevated sorafenib levels has been determined. Analyses of sorafenib AUC vs. PFS were not significant, although patients with the highest exposure (Quartile 4) had a numerically longer median PFS (509 days [95%CI: 283-623 days]) than those in the low (Q1) or medium (Q2+Q3) exposure groups (median PFS 305 days [95%CI: 162-448 days] and 293 days [95%CI: 231-451 days], respectively). There was no correlation between sorafenib AUC and incidence or severity of AEs (e.g. any AE, any SAE, any drug-related AE, hypertension, diarrhea, and hand-foot skin reaction). Conclusions: Sorafenib exposure was higher in DTC patients compared to patients with RCC and HCC. There was no apparent correlation between sorafenib exposure and PFS or AEs in DTC patients. This analysis is limited by the small number of subjects in each exposure subgroup and the single measurement of sorafenib AUC on Cycle 2-Day1. Clinical trial information: NCT 00895674.
What problem does this paper attempt to address?